Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Surrozen (Nasdaq: SRZN) announced an inducement stock option grant to newly appointed CFO Andrew P. Maleki.

On November 6, 2025 the board approved options covering 50,000 shares under the company’s 2025 Equity Inducement Plan, exercisable at $12.94 per share (Nasdaq closing price on November 12, 2025). The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continuous service.

The awards were granted as an inducement material to acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that on November 6, 2025, Surrozen granted inducement stock option awards covering an aggregate of 50,000 shares of Surrozen common stock to the newly appointed Chief Financial Officer, Andrew P. Maleki, as an inducement material to acceptance of employment with Surrozen.

The awards were granted under Surrozen’s 2025 Equity Inducement Plan and provides for the granting of equity awards to new employees of Surrozen in accordance with Nasdaq Listing Rule 5635(c)(4). The grant was approved by the Surrozen Board of Directors on November 6, 2025. The grant provides for the purchase of shares of Surrozen common stock at a price of $12.94 per share, the closing price per share of Surrozen common stock as reported by Nasdaq on November 12, 2025.

The stock option awards vest over a four-year period, with 25 percent of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date based on the employee date of hire, and the remaining shares vesting ratably each month on the same date as the vesting commencement date (or if there is no corresponding day, on the last day of the month), subject to the employee’s continuous service as of each such vesting date. The awards were granted as an inducement material to the new employee entering into employment with Surrozen, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to repair and restore tissue function, focused in ophthalmology. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling — alone or in combination with other key disease pathways — to address serious ophthalmic diseases with high unmet medical need. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes and create significant long-term value. For more information, visit www.surrozen.com.

Forward-Looking Statements 
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates); Surrozen’s intention to submit an IND application for SZN-8141 in 2026; and expectations regarding Surrozen’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Investor/Media Contact:
Email: Investorinfo@surrozen.com

FAQ

Who received the inducement grant from Surrozen (SRZN) on November 6, 2025?

Newly appointed CFO Andrew P. Maleki received the inducement stock option awards.

How many shares were included in the Surrozen (SRZN) inducement option grant and at what price?

The grant covers 50,000 shares with an exercise price of $12.94 per share.

What is the vesting schedule for the Surrozen (SRZN) inducement stock options?

Options vest over four years: 25% on the first anniversary, then remaining shares vest monthly thereafter, subject to continuous service.

Under what plan and Nasdaq rule were Surrozen (SRZN) inducement awards granted?

The awards were granted under the 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

When did Surrozen’s board approve the inducement option grant to the new CFO?

The Surrozen Board of Directors approved the grant on November 6, 2025.